Literature DB >> 16501837

Expression of serine protease matriptase in renal cell carcinoma: correlation of tissue microarray immunohistochemical expression analysis results with clinicopathological parameters.

Jong-Shiaw Jin1, Ann Chen, Dar-Shih Hsieh, Chen-Wen Yao, Ming-Fang Cheng, Yeh-Feng Lin.   

Abstract

Serine protease matriptase (matriptase) cleaves and activates proteins implicated in the progression of cancer and represents a potential therapeutic target. Immunohistochemical analysis of matriptase was performed in tissue microarrays of 168 renal cell carcinomas (RCCs). All subtypes of RCC showed significant immunohistochemical expression of matriptase. In contrast, no expression occurred in areas of RCC with sarcomatous differentiation (SRCC) and in normal collecting tubules. The matriptase scores were significantly higher in papillary RCC (341+/-28) and clear cell RCC with granular cell differentiation (GRCC; 324+/-27) than in other histologic subtypes of RCC. In GRCC, matriptase scores were correlated with TNM staging and nuclear grading. Matriptase was overexpressed in all subtypes of RCC, and matriptase scores could distinguish between conventional clear cell RCC, GRCC, and SRCC. Int J Surg Pathol 14(1):65-72, 2006.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16501837     DOI: 10.1177/106689690601400111

Source DB:  PubMed          Journal:  Int J Surg Pathol        ISSN: 1066-8969            Impact factor:   1.271


  11 in total

1.  β1,6-N-acetylglucosaminyltransferase V predicts recurrence and survival of patients with clear-cell renal cell carcinoma after surgical resection.

Authors:  Yidong Liu; Haiou Liu; Weisi Liu; Weijuan Zhang; Huimin An; Jiejie Xu
Journal:  World J Urol       Date:  2015-01-29       Impact factor: 4.226

2.  Tumor detection by imaging proteolytic activity.

Authors:  Molly R Darragh; Eric L Schneider; Jianlong Lou; Paul J Phojanakong; Christopher J Farady; James D Marks; Byron C Hann; Charles S Craik
Journal:  Cancer Res       Date:  2010-02-09       Impact factor: 12.701

3.  Expression and prognostic value of matriptase in ovarian serous adenocarcinoma.

Authors:  Mei Ji; Shunshuang Li; Ya Xie; Zhao Zhao; Weizhong Chang; Yue Li; Xinghan Cheng; Zhuo Wang
Journal:  Oncol Lett       Date:  2017-01-17       Impact factor: 2.967

4.  Imaging a functional tumorigenic biomarker in the transformed epithelium.

Authors:  Aaron M LeBeau; Minhee Lee; Stephanie T Murphy; Byron C Hann; Robert S Warren; Romelyn Delos Santos; John Kurhanewicz; Samir M Hanash; Henry F VanBrocklin; Charles S Craik
Journal:  Proc Natl Acad Sci U S A       Date:  2012-12-17       Impact factor: 11.205

5.  Microarray-based identification of CUB-domain containing protein 1 as a potential prognostic marker in conventional renal cell carcinoma.

Authors:  Yasuo Awakura; Eijiro Nakamura; Takeshi Takahashi; Hirokazu Kotani; Yoshiki Mikami; Tadashi Kadowaki; Akira Myoumoto; Hideo Akiyama; Noriyuki Ito; Toshiyuki Kamoto; Toshiaki Manabe; Hitoshi Nobumasa; Gozoh Tsujimoto; Osamu Ogawa
Journal:  J Cancer Res Clin Oncol       Date:  2008-05-16       Impact factor: 4.553

6.  Overexpression of matriptase correlates with poor prognosis in esophageal squamous cell carcinoma.

Authors:  Sang Yun Ha; Ki Yeon Kim; Nam Kyung Lee; Moon Gyo Kim; Seok-Hyung Kim
Journal:  Virchows Arch       Date:  2013-11-19       Impact factor: 4.064

Review 7.  Type II transmembrane serine proteases as potential targets for cancer therapy.

Authors:  Andrew S Murray; Fausto A Varela; Karin List
Journal:  Biol Chem       Date:  2016-09-01       Impact factor: 3.915

8.  Matriptase and MET are prominently expressed at the site of bone metastasis in renal cell carcinoma: immunohistochemical analysis.

Authors:  Shoichiro Mukai; Kenji Yorita; Yukari Kawagoe; Yuichi Katayama; Kozue Nakahara; Toyoharu Kamibeppu; Satoru Sugie; Hiromasa Tukino; Toshiyuki Kamoto; Hiroaki Kataoka
Journal:  Hum Cell       Date:  2014-09-04       Impact factor: 4.174

9.  Targeting the membrane-anchored serine protease testisin with a novel engineered anthrax toxin prodrug to kill tumor cells and reduce tumor burden.

Authors:  Erik W Martin; Marguerite S Buzza; Kathryn H Driesbaugh; Shihui Liu; Yolanda M Fortenberry; Stephen H Leppla; Toni M Antalis
Journal:  Oncotarget       Date:  2015-10-20

10.  Non-hematopoietic PAR-2 is essential for matriptase-driven pre-malignant progression and potentiation of ras-mediated squamous cell carcinogenesis.

Authors:  K U Sales; S Friis; J E Konkel; S Godiksen; M Hatakeyama; K K Hansen; S R Rogatto; R Szabo; L K Vogel; W Chen; J S Gutkind; T H Bugge
Journal:  Oncogene       Date:  2014-01-27       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.